Home › Trials › NCT05689151

Learning about Abrocitinib for treating moderate to severe atopic dermatitis in adults

Treating Atopic Dermatitis With Abrocitinib and Its Impact in Real Life: An Observational Cohort Study To Describe the Effectiveness of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis.

Observational Pfizer · NCT05689151

This study is testing if taking Abrocitinib daily can safely help adults with moderate to severe atopic dermatitis feel better over two years.

Quick facts

Study typeObservational
Enrollment183 (estimated)
Ages18 Years and up
SexAll
SponsorPfizer Industry-sponsored
Drugs / interventionsabrocitinib
Locations30 sites (Amiens, Somme and 29 other locations)
Trial IDNCT05689151 on ClinicalTrials.gov

What this trial studies

This observational study aims to evaluate the safety and effectiveness of Abrocitinib in adult patients suffering from moderate to severe atopic dermatitis in a real-world clinical setting. Participants, aged 18 and older, will take Abrocitinib daily while also using topical treatments for their condition. The study will last for 24 months, during which participants will visit the clinic approximately every 4 to 6 months to monitor their experiences and outcomes. The goal is to gather data that will help determine the medicine's safety and its impact on treating atopic dermatitis.

Who should consider this trial

Good fit: Ideal candidates are adults over 18 years old with a clinical diagnosis of moderate-to-severe chronic atopic dermatitis.

Not a fit: Patients who are contraindicated for Abrocitinib or unable to comply with study procedures may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the real-world effectiveness and safety of Abrocitinib for patients with atopic dermatitis.

How similar studies have performed: Other studies have shown promising results with JAK inhibitors like Abrocitinib for atopic dermatitis, indicating a potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patients older than 18 years of age at inclusion.
* Patients with clinical diagnosis of moderate-to-severe chronic atopic dermatitis (also referred to as atopic eczema) at inclusion according to the investigator and eligible for abrocitinib according to its marketing approval.
* Patients that have been informed of the study procedures and have signed the consent.

Exclusion Criteria:

* Patients for whom abrocitinib is contraindicated.
* Patients unable to follow and respect the study procedures and judged inapt to respond to the questions required for the study due to linguistical, psychological, social, or geographical reasons.
* Patients not affiliated to the French social security system.
* Patients deprived of liberty, under guardianship, or unable to provide oral consent.
* Patients participating in a clinical study assessing a medicinal treatment (patients can participate in registries and observatories).

Where this trial is running

Amiens, Somme and 29 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Atopic DermatitisEczemaAtopic dermatitisADAbrocitinibJAK inhibitorsFranceDermatitis
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.